Mostrar el registro sencillo

dc.contributor.authorMedina, Juan Manuel
dc.contributor.authorFernandez López, Raúl
dc.contributor.authorCrespo García, Javier 
dc.contributor.authorCruz Calahorra, Fernando de la 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-02-17T18:32:07Z
dc.date.available2022-02-17T18:32:07Z
dc.date.issued2021
dc.identifier.issn2077-0383
dc.identifier.otherBFU2017-86378-P
dc.identifier.urihttp://hdl.handle.net/10902/23982
dc.description.abstractChanges in the gut microbiome have been associated with inflammatory bowel disease. A protective role of short chain fatty acids produced by the gut microbiota has been suggested as a causal mechanism. Nevertheless, multi-omic analyses have failed to identify a clear link between changes in specific taxa and disease states. Recently, metagenomic analyses unveiled that gut bacterial species have a previously unappreciated genomic diversity, implying that a geno-centric approach may be better suited to identifying the mechanisms involved. Here, we quantify the abundance of terminal genes in propionate-producing fermentative pathways in the microbiome of a large cohort of healthy subjects and patients with inflammatory bowel disease. The results show that propionate kinases responsible for propionate production in the gut are depleted in patients with Crohn's disease. Our results also indicate that changes in overall species abundances do not necessarily correlate with changes in the abundances of metabolic genes, suggesting that these genes are not part of the core genome. This, in turn, suggests that changes in strain composition may be as important as changes in species abundance in alterations of the gut microbiome associated with pathological conditions.es_ES
dc.description.sponsorshipFunding: This work was funded by project BFU2017-86378-P from the Spanish Ministry of Science and Innovation (MCINN) to F.d.l.C.es_ES
dc.format.extent13 p.es_ES
dc.language.isoenges_ES
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceJ Clin Med . 2021 May 18;10(10):2176es_ES
dc.subject.otherShort Chain Fatty Acidses_ES
dc.subject.otherMicrobiotaes_ES
dc.subject.otherCrohn’s diseasees_ES
dc.subject.otherMetagenomicses_ES
dc.titlePropionate fermentative genes of the gut microbiome decrease in inflammatory bowel diseasees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/ 10.3390/jcm10102176es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/jcm10102176
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.